|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCNX4 |
Gene summary for PCNX4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCNX4 | Gene ID | 64430 |
| Gene name | pecanex 4 | |
| Gene Alias | C14orf135 | |
| Cytomap | 14q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q63HM2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64430 | PCNX4 | RNA-P17T-P17T-2 | Human | Lung | IAC | 4.30e-05 | 5.08e-01 | 0.3371 |
| 64430 | PCNX4 | RNA-P17T-P17T-4 | Human | Lung | IAC | 7.92e-03 | 3.25e-01 | 0.343 |
| 64430 | PCNX4 | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.46e-09 | 6.06e-01 | 0.3329 |
| 64430 | PCNX4 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 3.26e-05 | 7.70e-01 | -0.0263 |
| 64430 | PCNX4 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.99e-06 | 2.76e-01 | -0.0166 |
| 64430 | PCNX4 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.12e-08 | 3.17e-01 | -0.0132 |
| 64430 | PCNX4 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.97e-09 | 3.15e-01 | -0.013 |
| 64430 | PCNX4 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.00e-02 | 2.34e-01 | -0.0121 |
| 64430 | PCNX4 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 1.78e-02 | 3.66e-01 | -0.0809 |
| 64430 | PCNX4 | HTA12-15-2 | Human | Pancreas | PDAC | 7.26e-07 | 6.06e-01 | 0.2315 |
| 64430 | PCNX4 | HTA12-23-1 | Human | Pancreas | PDAC | 2.07e-02 | 5.65e-01 | 0.3405 |
| 64430 | PCNX4 | HTA12-26-1 | Human | Pancreas | PDAC | 9.38e-10 | 6.57e-01 | 0.3728 |
| 64430 | PCNX4 | HTA12-29-1 | Human | Pancreas | PDAC | 4.10e-25 | 6.74e-01 | 0.3722 |
| 64430 | PCNX4 | male-WTA | Human | Thyroid | PTC | 1.41e-16 | 1.22e-01 | 0.1037 |
| 64430 | PCNX4 | PTC01 | Human | Thyroid | PTC | 2.67e-08 | 1.11e-01 | 0.1899 |
| 64430 | PCNX4 | PTC04 | Human | Thyroid | PTC | 3.24e-13 | 2.79e-01 | 0.1927 |
| 64430 | PCNX4 | PTC05 | Human | Thyroid | PTC | 2.01e-10 | 3.59e-01 | 0.2065 |
| 64430 | PCNX4 | PTC06 | Human | Thyroid | PTC | 1.72e-13 | 4.01e-01 | 0.2057 |
| 64430 | PCNX4 | PTC07 | Human | Thyroid | PTC | 3.21e-16 | 3.79e-01 | 0.2044 |
| 64430 | PCNX4 | ATC09 | Human | Thyroid | ATC | 8.87e-17 | 4.13e-01 | 0.2871 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCNX4 | SNV | Missense_Mutation | novel | c.1684A>C | p.Thr562Pro | p.T562P | Q63HM2 | protein_coding | deleterious(0) | benign(0.368) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| PCNX4 | SNV | Missense_Mutation | novel | c.1684A>C | p.Thr562Pro | p.T562P | Q63HM2 | protein_coding | deleterious(0) | benign(0.368) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCNX4 | SNV | Missense_Mutation | novel | c.1712N>C | p.Val571Ala | p.V571A | Q63HM2 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PCNX4 | SNV | Missense_Mutation | novel | c.1684N>C | p.Thr562Pro | p.T562P | Q63HM2 | protein_coding | deleterious(0) | benign(0.368) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PCNX4 | SNV | Missense_Mutation | novel | c.1684A>C | p.Thr562Pro | p.T562P | Q63HM2 | protein_coding | deleterious(0) | benign(0.368) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PCNX4 | SNV | Missense_Mutation | novel | c.1684A>C | p.Thr562Pro | p.T562P | Q63HM2 | protein_coding | deleterious(0) | benign(0.368) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| PCNX4 | SNV | Missense_Mutation | novel | c.1684N>C | p.Thr562Pro | p.T562P | Q63HM2 | protein_coding | deleterious(0) | benign(0.368) | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| PCNX4 | insertion | Nonsense_Mutation | novel | c.2960_2961insATTTGTACCTGGCAAATCTTTCAACTGATGT | p.Asn987LysfsTer10 | p.N987Kfs*10 | Q63HM2 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PCNX4 | insertion | Frame_Shift_Ins | novel | c.2978_2979insCAAATCTT | p.His994LysfsTer6 | p.H994Kfs*6 | Q63HM2 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PCNX4 | insertion | Frame_Shift_Ins | novel | c.2390_2391insAA | p.Leu798IlefsTer2 | p.L798Ifs*2 | Q63HM2 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |